Celularity Inc CELU

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies

derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and

severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality

towards the end of life. Aging is known to be a major risk factor for many degenerative disorders and diseases across multiple

Last close 0.98 2026-10-23
Market cap $28.3M 2025-12-31 share count
52-week range 0.56 - 2.55

Valuation FY2025 figures against the last close

P/S1.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.59

Where the revenue comes from as reported in the latest 10-K

Revenue by segment

  • Degenerative Disease
  • Biobanking
  • Cell Therapy
Revenue by segment, 3 categories over 2 years. The same figures are in the table below. FY2025 Degenerative Disease, FY2025: 17.3M (65.2%) 65% Degenerative Disease Biobanking, FY2025: 5.4M (20.5%) 20% Biobanking Cell Therapy, FY2025: 3.8M (14.3%) 14% Cell Therapy FY2024 Degenerative Disease, FY2024: 48.4M (89.3%) 89% Biobanking, FY2024: 5.1M (9.5%) 9% Cell Therapy, FY2024: 688K (1.3%)
Segment FY2025FY2024
Degenerative Disease $17.3M $48.4M
Biobanking $5.4M $5.1M
Cell Therapy $3.8M $688.0K

As the company reported it, from the “Schedule of Financial Information by Segment (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $26.6M$54.2M$22.8M$18.0M$21.3M$14.3M——
Cost of revenue $20.1M$15.0M$16.0M—————
Gross profit $6.5M$39.2M$6.8M-$1.7M$11.7M$9.3M——
R&D $15.0M$17.4M$30.5M$78.4M$88.4M$52.7M——
SG&A $51.3M$58.6M$50.6M$66.0M$71.3M$31.3M——
Operating income -$61.3M-$38.4M-$192.3M-$25.6M-$109.1M-$151.9M-$1.7M—
Pre-tax income -$91.7M-$57.9M-$196.3M$14.2M-$100.1M-$212.9M$6.5M—
Income tax $3.0K—$10.0K$13.0K$20.0K$4.7M$668.2K—
Net income -$91.7M-$57.9M-$196.3M$14.2M-$100.1M-$208.2M$5.9M—
EPS, basic -3.59-2.64-11.021.01-1.49———
EPS, diluted -3.59-2.64-11.020.95-1.49-11.310.10—
Shares, diluted (wtd. avg.) 25.6M21.9M17.8M15.0M67.1M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $6.2M$738.0K$10.2M$28.8M$52.1M$69.5M$43.5M$24.7K
Inventory $571.0K$5.4M$5.8M$5.3M$9.5M$3.9M——
Total current assets $12.3M$20.6M$19.8M$33.5M$59.1M$72.2M$1.0M$24.7K
Property, plant and equipment $55.8M$61.6M$67.8M$75.7M$90.6M$90.1M——
Goodwill $7.3M$7.3M$7.3M$119.7M$123.3M$123.3M$127.1M—
Other intangibles $7.8M$9.2M$11.0M$121.0M$123.2M$125.4M——
Total assets $107.3M$132.7M$143.9M$401.1M$414.1M$431.0M$291.6M$174.5K
Accounts payable $26.4M$23.3M$14.1M$5.8M$9.3M$5.4M$210.2K$555
Short-term debt —$42.7M$17.2M$37.6M————
Total current liabilities $80.8M$53.7M$67.3M$62.1M$26.2M$26.7M$229.1K$150.6K
Total liabilities $145.4M$123.8M$102.9M$202.2M$314.7M$412.3M$28.2M$150.6K
Retained earnings -$991.5M-$899.7M-$841.8M-$645.5M-$663.7M-$563.6M$3.9M-$1.1K
Total equity -$38.1M$8.8M$41.0M$198.9M$99.4M-$531.4M-$327.4M$23.9K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow -$13.3M-$6.4M-$38.7M-$137.9M-$110.1M-$63.2M-$1.1M—
Depreciation and amortisation $7.3M$7.9M$9.3M$9.4M$8.8M$8.2M——
Stock-based compensation ——$0—————
Capital expenditure —$161.0K$1.0M$5.2M$6.2M$27.8M——
Investing cash flow —$514.0K-$4.0M-$5.2M-$5.9M-$12.8M-$286.8M—
Financing cash flow $18.6M$6.7M$24.1M$119.8M$98.6M$102.0M$288.8M—
Buybacks —————$256.0K——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020424.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -300M -200M -100M 0 100M Net income, FY2019: 5.9M Revenue, FY2020: 14.3M Gross profit, FY2020: 9.3M Net income, FY2020: -208.2M Revenue, FY2021: 21.3M Gross profit, FY2021: 11.7M Net income, FY2021: -100.1M Revenue, FY2022: 18M Gross profit, FY2022: -1.7M Net income, FY2022: 14.2M Revenue, FY2023: 22.8M Gross profit, FY2023: 6.8M Net income, FY2023: -196.3M Revenue, FY2024: 54.2M Gross profit, FY2024: 39.2M Net income, FY2024: -57.9M Revenue, FY2025: 26.6M Gross profit, FY2025: 6.5M Net income, FY2025: -91.7M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — $14.3M $21.3M $18.0M $22.8M $54.2M $26.6M
Gross profit — — $9.3M $11.7M -$1.7M $6.8M $39.2M $6.5M
Net income — $5.9M -$208.2M -$100.1M $14.2M -$196.3M -$57.9M -$91.7M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Delisting notice Item 3.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%